• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Scientific Officer Hartley Dylan

    10/8/24 7:24:46 PM ET
    $RPHM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RPHM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hartley Dylan

    (Last) (First) (Middle)
    C/O ONKURE THERAPEUTICS, INC.
    6707 WINCHESTER CIRCLE, SUITE 400

    (Street)
    BOULDER CO 80301

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OnKure Therapeutics, Inc. [ OKUR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientific Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    10/04/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (right to buy) $18.2 10/04/2024 A 137,603 (1) 10/03/2034 Class A Common Stock 137,603 $0 137,603 D
    Explanation of Responses:
    1. 1/4th of the shares subject to the option shall vest on June 9, 2025 and 1/48th of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
    /s/ Rogan Nunn, by power of attorney 10/08/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RPHM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RPHM

    DatePrice TargetRatingAnalyst
    12/15/2023Outperform → Market Perform
    Leerink Partners
    12/15/2023Buy → Hold
    Jefferies
    12/15/2023$30.00 → $1.50Buy → Neutral
    H.C. Wainwright
    12/14/2023Buy → Neutral
    Ladenburg Thalmann
    12/14/2023$23.00 → $1.45Buy → Underperform
    BofA Securities
    12/14/2023Outperform → Mkt Perform
    William Blair
    12/14/2023$28.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/14/2023$25.00 → $4.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $RPHM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

      -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 -- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026 -- Shares to trade on Nasdaq under the new ticker symbol "OKUR" commencing on October 7, 2024 BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR) ("OnKure"), a clinical-stage biopharmaceutical company focused on the develo

      10/4/24 4:57:48 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

      – Combined company to trade on Nasdaq under ticker "OKUR" – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) ("Reneo") today announced the results of the special meeting of its stockholders held on September 26, 2024. At the special meeting, Reneo's stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure, Inc. ("OnKure"). The closing of the merger is anticipated to take place on or around Friday, October 4, 2024. Following the closing of the merger, the combined company plans to change its name from "Reneo Pharmaceut

      10/2/24 8:20:45 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

      IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the second quarter ended June 30, 2024. Second Quarter and Recent Highlights On May 10, 2024, Reneo and OnKure, Inc. entered into a definitive merger agreement to combine the companies in an all-stock transaction (the "Merger").The Merger is expected to create a Nasdaq-listed, clinical stage biopharmaceutical company focused on advancing OnKure's portfolio of precision oncology therapies.The Merger a

      8/13/24 7:35:00 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Leadership Updates

    Live Leadership Updates

    See more
    • Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

      SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

      3/25/24 7:00:00 AM ET
      $IPSC
      $MIRM
      $RPHM
      $SGMT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

      IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the company's Board of Directors. "Roshawn is an accomplished leader within the biopharma industry," said Mike Grey, Executive Chairman of Reneo Pharmaceuticals. "Her extensive experience in healthcare reimbursement, policy, and patient access will be an invaluable addition to Reneo as we plan for commercialization of REN001 in the U.S. and Europe. We look forward to working with Roshawn o

      8/2/22 7:30:00 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals Announces Changes to its Board of Directors

      IRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed to the Board and will serve as chair of the Audit Committee. In conjunction with the appointment of Mr. Hoelscher, Kenneth Harrison, Partner at Novo Ventures (US) Inc., resigned from the Reneo Board of Directors. Reneo also today announced that Lon Cardon, Ph.D. will not seek

      1/24/22 8:00:00 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Leonard Braden Michael bought $144,738 worth of shares (98,346 units at $1.47) (SEC Form 4)

      4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)

      9/26/24 9:33:44 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $76,237 worth of shares (56,106 units at $1.36) (SEC Form 4)

      4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)

      9/19/24 11:02:54 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $484,344 worth of shares (358,923 units at $1.35) (SEC Form 4)

      4 - Reneo Pharmaceuticals, Inc. (0001637715) (Issuer)

      9/16/24 4:15:23 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    SEC Filings

    See more
    • Reneo Pharmaceuticals Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Regulation FD Disclosure

      8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)

      10/8/24 5:26:01 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by Reneo Pharmaceuticals Inc.

      425 - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)

      10/2/24 5:23:57 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Reneo Pharmaceuticals Inc.

      8-K - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)

      10/2/24 5:20:31 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Saccomano Nicholas A was granted 4,556 shares (SEC Form 4)

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      10/8/24 7:29:45 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Phillips Andrew John

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      10/8/24 7:28:32 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mathers Edward T

      4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)

      10/8/24 7:27:58 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Reneo Pharmaceuticals downgraded by Leerink Partners

      Leerink Partners downgraded Reneo Pharmaceuticals from Outperform to Market Perform

      12/15/23 8:31:56 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals downgraded by Jefferies

      Jefferies downgraded Reneo Pharmaceuticals from Buy to Hold

      12/15/23 8:31:34 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reneo Pharmaceuticals downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Reneo Pharmaceuticals from Buy to Neutral and set a new price target of $1.50 from $30.00 previously

      12/15/23 6:59:38 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RPHM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Reneo Pharmaceuticals Inc.

      SC 13D/A - OnKure Therapeutics, Inc. (0001637715) (Subject)

      10/8/24 7:34:57 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Reneo Pharmaceuticals Inc.

      SC 13G - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)

      9/26/24 4:00:22 PM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Reneo Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)

      5/21/24 10:12:24 AM ET
      $RPHM
      Biotechnology: Pharmaceutical Preparations
      Health Care